The Response of New GA Therapies From Patients, Payers | ASRS 2023
In an interview with MHE, Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, talked about the latest geographic atrophy treatments, pegcetacoplan and avacincaptad pegol, from a coverage and healthcare resource utilization standpoint, as both will potentially be available for the chronic disease that previously had no treatments.
Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, talked about the latest geographic atrophy treatments, pegcetacoplan and avacincaptad pegol, from a coverage and healthcare resource utilization standpoint, as both treatments will be potentially available for the chronic disease that previously had no treatments.
As as a retina specialist, Hahn mentioned he is witnessing patients coming into the doctor's office asking for these treatments.
"It's exciting that we have one treatment option currently, and it's very exciting that we may soon have another," he said. "I'm not sure how those will interplay together, (but) I think as a field, we need to figure out where each of those fit into our armamentarium."
Changes to Susvimo Port Delivery System Explained | ASRS 2024
July 22nd 2024Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.
Read More
Results from retrospective real-world studies presented at American Society of Retina Specialists annual meetiing put the risk of retinal vasculitis from Syfovre at 1 in 1,330 patients. But other results presented at the meeting supplied evidence that Syfovre fends off vision loss caused by geographic atrophy, an advanced form of dry age-related macular degeneration.
Read More
